Paola Facheris

Dec 18, 2023 | onlinelibrary.wiley.com | Emma Guttman-Yassky |Paola Facheris |Pedro Jesús Gómez-Arias |Ester Del Duca

1 BACKGROUND Atopic dermatitis (AD) is a chronic inflammatory skin disease with complex pathophysiology,1 characterized by skin barrier dysfunction, innate immune system activation, and T-helper 2 (Th2)- and Th22-driven inflammation.2 Th1 and Th17 activation in AD may also play a role alongside Th2/Th22 inflammation and varies by patient race and age.3 Oral abrocitinib is approved for the treatment of moderate-to-severe AD.4 Abrocitinib 200 mg or 100 mg once daily (QD) demonstrated greater...

Nov 20, 2023 | onlinelibrary.wiley.com | Robert Bissonnette |Janet Dubois |Paola Facheris |Ester Del Duca

CCL17 C-C motif chemokine ligand 17 CCL22 C-C motif chemokine ligand 22 CCR4 C-C motif chemokine receptor 4 EASI Eczema Area and Severity Index EOT end of treatment MAD multiple ascending dose MADAD meta-analysis derived atopic dermatitis NL non-lesional SAD single ascending dose SCORAD SCORing Atopic Dermatitis Th T-helper cell 1 INTRODUCTION Atopic dermatitis (AD) is a chronic inflammatory skin disease that is estimated to affect ~15%–20% of children and up to 10% of adults worldwide, with...